NCT00873093 · OUTCOME

Severe Adverse Events (SAE) Rate.

Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · Source last updated 2017-01-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: 4 months

What was measured

The proportion of SAE rate among all eligible patients

Analysis population: The SAE event was monitored for all eligible patients. It was not compared between subgroups per protocol 9.3.2.

Groups in this outcome

Overall

All enrolled eligible patients.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Overall	146

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Overall	8.2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
8.2

denoms

counts
group Id
OG000
value
146
units
Participants

description

The proportion of SAE rate among all eligible patients

groups

description
All enrolled eligible patients.
id
OG000
title
Overall

param Type

NUMBER

population Description

The SAE event was monitored for all eligible patients. It was not compared between subgroups per protocol 9.3.2.

reporting Status

POSTED

time Frame

4 months

title

Severe Adverse Events (SAE) Rate.

type

PRIMARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice